Earlier this month, biopharmaceutical company Bristol Myers Squibb (BMS), published the Dutch results of a deep-dive survey that the company set up as part of its ‘Because there is more to do’ initiative. Patients, caregivers and healthcare providers indicated what their biggest challenges are during the disease process, how they feel about pharmaceutical companies and where they think pharma can provide more support. The publication of the report is the starting point for further consultations with different healthcare actors, with new collaborations and relevant actions as the final goal.
If you want to know and learn more about patients' needs for mental and emotional support during their treatment, please join their European Because There is More to Do Summit on September 30. Results from the surveys will be shared by leading experts from 8 European countries. To register for the event, please click here.
